OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, furnished this Form 6-K on November 25, 2022. The report relates to an announcement issued on November 24, 2022 regarding the grant of options and a person discharging managerial responsibilities (PDMR) dealing.
Financial and Operating Metrics
The filing contains no financial statements or information on revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes Versus Prior Period
The filing text does not provide a comparable-period analysis. The reported corporate action is the grant of options involving a PDMR, but the terms and potential dilution are not included in the filing text provided.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk update, contingency, or unusual financial item is disclosed. Exhibit 99.1 is identified as the related news announcement, but its substantive contents are not included in the provided text.
Investor Verification Items
- Verify the number, exercise price, vesting conditions, expiration date, and recipients of the options.
- Assess the potential share dilution and any related-party or PDMR disclosure.
- Review Exhibit 99.1, dated November 24, 2022, for the complete terms of the announcement.
- Note that the exhibit is furnished and generally not deemed filed for purposes of Section 18 of the Securities Exchange Act.